Werner Lanthaler, Evotec CEO (Argenx)

A ma­jor new in­vestor just ar­rived at the biotech par­ty, as Evotec nets $295M from Mubadala and No­vo

Ger­many’s Evotec has a new mi­nor­i­ty stake­hold­er, one that’s pro­vid­ing a hefty heap­ing of ini­tial cash.

Mubadala In­vest­ment Com­pa­ny, the UAE’s sov­er­eign wealth fund, has ac­quired $236 mil­lion worth of shares in a pri­vate place­ment, good for about 5.6% of the com­pa­ny. The fund pur­chased the shares at $25.67, with Evotec giv­ing Mubadala a 3.4% dis­count on its price at mar­ket close Mon­day.

In ad­di­tion, ex­ist­ing in­vestor No­vo in­creased its stake in Evotec to 11% by chip­ping in an­oth­er $59 mil­lion. That brings the to­tal sum raised to about $295 mil­lion, or €250 mil­lion flat.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.